The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

On October 23, 2026, Phathom Pharmaceuticals, Inc. announced that BDR Pharmaceuticals International Pvt. Ltd. has filed suit against the U.S. Food and Drug Administration and related Federal ...

Investors in Phathom Pharmaceuticals, Inc. PHAT need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 15, 2027 $30 Call had some of the highest ...

Hello and welcome to the Phathom Pharmaceuticals’ First Quarter 2025 Earnings Results Call. [Operator Instructions] Please be advised that today’s conference is being recorded. With that, I would like ...

Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI Oct. 29 Phathom Pharmaceuticals, Inc. Maintains Earnings Guidance for the Full ...

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -42.86% and -1.71%, respectively, for the quarter ...

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of ...

All right. I think we're ready to go. Welcome to the last presentation of the day at the Barclays Miami Healthcare Conference. My name is Jenna Davidner. I'm one of the analysts on the specialty ...

Three scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, ...

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $1.42 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to loss of $0.89 per share a year ago.